Key result
Fenofibrate and CoQ10 fail to improve diastolic function over placebo in T2D patients with LVDD.
Why the study?
The effects of fenofibrate and coenzyme Q10 on diastolic function, ambulatory blood pressure, and heart rate in type 2 diabetic subjects with LVDD were not well established.
Does fenofibrate and/or coenzyme Q10 improve diastolic function or hemodynamics in type 2 diabetic subjects with left ventricular diastolic dysfunction?
Population
74 type 2 diabetic subjects with left ventricular diastolic dysfunction
Comparison
Fenofibrate 160 mg daily, CoQ 200 mg daily, fenofibrate plus CoQ, vs matching placebo
Design
Randomized double-blind controlled trial
Follow-up
6 months
Authors
Loading...
No diastolic function benefit with fenofibrate or CoQ10 in diabetic LVDD; challenges prior hypotheses while leaving BP/HR effects open for targeted trials.
RCT (n=74)
Double-blind
randomized
Does fenofibrate and/or coenzyme Q10 improve diastolic function or hemodynamics in type 2 diabetic subjects with left ventricular diastolic dysfunction?
p-value: p=>0.05
In patients with type 2 diabetes and left ventricular diastolic dysfunction, 6 months of therapy with fenofibrate and/or coenzyme Q10 does not improve echocardiographic measures of diastolic function, despite modest reductions in ambulatory blood pressure.
Chew et al. (2008) conducted an RCT in Type 2 diabetes with left ventricular diastolic dysfunction (n=74). Fenofibrate and coenzyme Q10 vs. Placebo was evaluated on Diastolic function (E', E/A, deceleration time, isovolumic relaxation time, E/E') (p=>0.05). Neither fenofibrate nor coenzyme Q10, alone or in combination, significantly improved diastolic function compared with placebo in type 2 diabetic subjects with LVDD (P>0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: